FX医药公司一体化并购战略研究

发布时间：2018-04-21 15:07

本文选题：FX医药公司 + 并购战略　；参考：《天津财经大学》2014年硕士论文

【摘要】：随着国际化竞争的加剧、我国医药管理体制的改革和医药十五规划的出台,我国大部分医药企业选择了战略并购之路。他们希望通过战略并购之路扩大自已的规模,形成自己的核心竞争力和产业结构。但是就如何提高并购的成功率,在并购之后如何应对更加严峻的整合挑战,我国许多医药企业仍然十分茫然,这也是国内医药企业并购成功率不高的重要原因。在这种现实背景下,我们就非常值得关注和研究FX医药公司究竟是如何通过战略并购,成功地实现企业超常规、跨越式发展的经典案例了。在2011年至2013年期间,作者通过大量收集和整理相关的调研报告、访谈报告和公开信息,并与部分调研者进行了沟通,最终获得了大量关于FX医药公司的翔实材料。从总体上看,全文共分为六部分：第一部分,全文导论,总结国内外关于企业并购的研究,阐述文章创新点及研究框架。第二部分,首先论述并购战略的相关理论,详细介绍比较流行的几种并购理论。其次,重点介绍一体化并购战略理论,为本文的进一步论述打下坚实的理论基础。第三部分,介绍FX医药公司的并购的背景,重点分析的医药行业背景,以及运用PEST分析法对FX医药公司所处的内外部环境进行细致的分析,使读者对FX医药公司有一个整体的了解。第四部分,运用价值链分析法,对FX医药公司并购战略的选择加以设计,得出要进行一体化并购战略的结论。进一步对一体化战略如何实施进行了进一步详细阐述。第五部分,对FX医药公司采取一体化并购战略后取得的效果进行了逐一评价。第六部分,阐述了FX医药公司一体化并购战略得出的启示。本文运用PEST分析法、价值链分析法、核心竞争力理论、一体化战略理论、并购理论等为理论依据,就FX医药公司的并购战略、目标、方式及并购后的整合进行了全面而深入的分析,总结了其成功之处,从而启发正在进行战略并购的国内医药企业。
[Abstract]:With the intensification of international competition, the reform of pharmaceutical management system and the introduction of the 10th Five-Year Plan of Medicine, most pharmaceutical enterprises in China have chosen the road of strategic merger and acquisition. They hope to expand their own scale through strategic mergers and acquisitions to form their core competitiveness and industrial structure. However, how to improve the success rate of M & A and how to deal with the more severe integration challenges after M & A, many pharmaceutical enterprises in China are still at a loss, which is also an important reason for the low success rate of M & A of domestic pharmaceutical enterprises. Under this kind of realistic background, we should pay close attention to and study the classic case of FX Pharmaceutical Company how to successfully realize the extraordinary and leap-forward development of the enterprise through strategic merger and acquisition. From 2011 to 2013, the author collected and collated extensive research reports, interviews and public information, and communicated with some of the researchers, resulting in a large amount of detailed materials about FX Pharmaceuticals. On the whole, the full text is divided into six parts: the first part, the introduction of the full text, summarizes the domestic and foreign research on mergers and acquisitions, expounds the innovation of the article and the research framework. In the second part, the related theories of M & A strategy are discussed, and several popular M & A theories are introduced in detail. Secondly, the integration merger strategy theory is introduced, which lays a solid theoretical foundation for the further discussion of this paper. The third part introduces the background of the merger and acquisition of FX Pharmaceutical Company, focuses on the pharmaceutical industry background, and makes a detailed analysis of the internal and external environment of FX Pharmaceutical Company by using the PEST analysis method. Give readers an overall understanding of FX Pharmaceuticals. In the fourth part, by using value chain analysis, the author designs the M & A strategy of FX Pharmaceutical Company, and draws the conclusion that the M & A strategy should be integrated. How to implement the integration strategy is further elaborated. In the fifth part, the author evaluates the effect of FX Pharmaceutical Company after adopting the strategy of M & A one by one. The sixth part, elaborated FX medicine company integration merger and acquisition strategy obtains enlightenment. Based on PEST analysis, value chain analysis, core competitiveness theory, integration strategy theory, M & A theory and so on, this paper aims at the M & A strategy of FX Pharmaceutical Company. The way and the integration after M & A are analyzed comprehensively and deeply, and the success of M & A is summarized, thus enlightening the domestic pharmaceutical enterprises in strategic M & A.
【学位授予单位】：天津财经大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：F271;F426.72

【相似文献】